



Diabetes, Metabolic Syndrome and Cardiovascular Disease

Published: 2009-APR-01

Pages: 265

Format: PDF

Description

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Table of Contents

1. Overview 8
 - 1.1 Statement of Report 8
 - 1.2 About this Report 8
 - 1.3 Scope of the Report 9
 - 1.4 Methodology 9
 - 1.5 Executive Summary 11
2. Introduction 17
 - 2.1 Demographics of Diabetes 17
 - 2.1.1 Worldwide Diabetes 17
 - 2.1.2 U.S. Diabetes 18
 - 2.2 Economics of Diabetes 22
3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 28
 - 3.1 Pre-Diabetes Syndrome 29
 - 3.2 Metabolic Syndrome 29
 - 3.3 Diabetes and Inflammation 32
 - 3.4 Progression of Diabetes 32
 - 3.5 Complications and Co-Morbidities in Type 2 Diabetes 33
 - 3.6 Hypoglycemia and Treatment 38
 - 3.7 Risk Factors and Diabetes 39
 - 3.8 Cardiovascular Disease (CVD) Facts 40
4. Pharmaceutical Industry and the Anti-Diabetes Market 51
 - 4.1 The Worldwide Pharmaceutical Industry 51
 - 4.2 Total Diabetes Drug Market Size and Growth 58
 - 4.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 61
 - 4.3 Epidemiology/Cost of Treatment 62
 - 4.4 Diabetic Medications Overview 63
 - 4.4.1 Recent Trends in Diabetic Drug Usage 63
 - 4.4.2 Market Influence Factors 67
5. Non-Insulin Anti-Diabetes Products 69
 - 5.1 Anti-Diabetic Drug Therapy Overview 69

5.1.1	Sulfonylureas	72
5.1.2	Meglitinides	73
5.1.3	Biguanides	73
5.1.4	Thiazolidinediones (TZDs)	74
5.1.5	α -Glucosidase Inhibitors	77
5.1.6	Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analog	77
5.1.7	Amylin Analog	79
5.1.8	DPP-IV Inhibitors	79
5.1.9	Other Classes	81
5.1.10	Combination Therapy	81
5.2	Drivers and Trends	82
5.2.1	Market Share of Anti-Diabetic Drugs	82
5.2.2	Forecasts for Anti-Diabetic Drugs	82
5.2.3	Sales Forecast for the Global Diabetes Market	83
5.3	The Future	84
5.3.1	Practice Patterns	84
5.3.2	New Products in Pipeline	85
5.4	Anti-Diabetic Drug Patent Expiry	91
5.5	Regulatory Issues	91
6.	Insulin	92
6.1	Insulin Markets	92
6.1.1	Major Players and Market Share	93
6.2	Insulin and Analogs	95
6.2.1	Rapid-Acting Insulin	95
6.2.2	Intermediate-Acting Insulin	97
6.2.3	Long-Acting Insulin/Ultra Long-Acting Insulin	97
6.2.4	Insulin Mixtures	99
6.3	Insulin Analogs	100
6.4	Non-Insulins in Development	100
6.5	Pipeline Insulin	101
6.6	Non-Invasive Insulin Delivery	101
6.6.1	Inhaled Insulin	101
6.6.1.1	Inhaled Insulin Overview	102
6.6.2	Oral Insulin	104
6.6.3	Transdermal Insulin	106
6.6.4	Oral Spray Insulin	108
6.7	Barriers for Non-Injected Insulin	109
6.8	Patient Potential for Non-Injected Insulin	109
6.9	Insulin Delivery Devices	109
6.9.1	Lancets and Lancing Devices	110
6.9.2	Insulin Pens	113
6.9.3	Injection Aids	117
6.9.3.1	Automatic Injectors	117
6.9.3.2	Syringe Magnifiers	118
6.9.3.3	Insulin Infusers	118
6.9.4	Insulin Jet Injectors	118
6.9.5	Insulin Pumps	119
6.9.5.1	External Insulin Pumps	119
6.9.5.2	Implantable Insulin Pumps	122
6.9.5.3	Insulin Pump Market Share	123
6.9.5.4	Drivers of Demand for Pumps	128
6.10	Market Forecasts for Insulin Administration Technologies	129
7.	Emerging Anti-Diabetes Products	130
7.1	Projections for the Anti-Diabetes Drug Market	130
7.2	Artificial Pancreas	134
7.3	Insulin-Producing Cells	135
7.3.1	Cell Therapy Companies for Diabetes	135
7.4	Transplantation Procedures	137
7.4.1	Pancreatic Transplantation	138
7.4.1.1	Pancreatic Organ Transplantation	138
7.4.1.2	Allo-Islet Transplantation	138
7.4.1.3	Transplantation of Encapsulated Pancreatic Cells	139
7.4.1.4	Implantation of Genetically Engineered-Cells or Embryonic Stem Cells	139
7.4.2	Current Status	140
7.5	Gastric Bypass Surgery to Treat Type 2 Diabetes	140
7.6	Immune Modulators	141
7.7	Anti-Obesity Drug Xenical to Prevent or Delay Development of Type 2 Diabetes	141
7.8	Other Anti-Diabetic Therapy Drug Candidates	141
7.8.1	Lipid Abnormalities	142
7.8.2	High Blood Pressure	143
7.8.3	Anticoagulants	144
7.9	Drugs Used "Off-Label"	145
7.9.1	Niacin Derivatives	145
7.9.2	Benfluorex	145
7.9.3	D-Chiro-Inositol	145

7.9.4	Warfarin Sodium	145
7.10	Pipeline Diabetic Drug Candidates	146
7.11	Drug Research Overview	149
7.12	Future Anti-Diabetic Drugs in Late-Stage Development	151
8.	Diagnosing Diabetes Using In Vitro Laboratory Tests	154
8.1	New Diagnostic Guidelines	154
8.2	Diabetes Tests	155
8.2.1	Fasting Plasma Glucose (FPG) Test	155
8.2.2	Glucose Tolerance Test	155
8.2.3	Test for Glycosylated Hemoglobin	156
8.2.4	Fructosamine	157
8.3	Glucose Monitoring	157
8.3.1	Overview of Market Segment	160
8.3.2	Competitive Strategies	160
8.3.3	Analyses of the Current Market Conditions, Competition and Product Mix	162
8.3.3.1	First-Generation Monitors	162
8.3.3.2	Second-Generation Monitors	162
8.3.3.3	Third-Generation SMBG Technologies	164
8.3.3.4	Product Overview	165
8.3.3.4.1	LifeScan	165
8.3.3.4.2	Roche Diagnostics	168
8.3.3.4.3	Bayer Diagnostics	169
8.3.3.4.4	Abbott Diagnostics	172
8.3.3.4.5	Other Players	174
8.3.4	What Are the Advantages of Using a Continuous Glucose-Monitoring Device?	177
8.3.5	Other Monitoring Device Advancements	178
8.3.6	Future of Non-Invasive Glucose Technology	179
9.	Market Trends, Challenges and Strategic Options	182
9.1	Overview	182
9.2	Diabetes Drug Market Trends	182
9.2.1	Overview	182
9.2.2	Emergence of Therapeutics with Improved Administration Characteristics	182
9.2.3	Increasing Prevalence of Obesity	183
9.3	Diabetes Mellitus Market Challenges	185
9.3.1	Overview	185
9.3.2	Diabetic Pain Therapeutics	185
9.3.3	Market Prospects of Inhalable Drugs and Their Ability to Establish Safety Levels	186
9.3.4	Changing Consumer Preference Drives Product Development in Invasive Technology Segment	186
9.3.5	Non-Invasive Technology for Revenue Potential	186
9.3.6	Developing Countries Emerging as Key Markets for Diabetes Monitoring Devices	187
9.3.7	Consumer-Driven Marketing Campaigns—Essential, though Expensive	189
9.3.8	Escalating Expenditure for R&D and Marketing Triggers Consolidation	189
9.3.9	Market Size Predictions	191
9.3.10	Major Competitors	191
9.4	Strategic Options	192
9.4.1	Overview	192
9.4.2	Combined Self-Testing Glucose Monitor with Insulin Delivery	193
9.4.3	Diabetes Drugs in Pipeline	194
9.5	FDA Therapeutic Targets	196
9.5.1	FDA Targets Cardiotoxicity	197
9.5.2	Avandia FDA Warning	197
9.6	Outlook to Anti-Diabetes Drugs	197
9.7	Outlook for Cardiovascular Drugs	201
10.	Company Profiles	203
10.1	A. Menarini	203
10.2	Abbott Laboratories	203
10.3	Amgen	204
10.4	AstraZeneca	205
10.5	Bayer	206
10.6	BodyMedia	208
10.7	Cybermedical	208
10.8	Debiotech	208
10.9	DexCom	209
10.10	Echo Therapeutics	210
10.11	Elixir Pharmaceuticals	211
10.12	Eksigent	211
10.13	Flamel Technologies	211
10.14	GlaxoSmithKline	212
10.15	GlucoLight	212
10.16	Insulet	212
10.17	iSense Corporation	213
10.18	Isis Pharmaceuticals, Inc.	213
10.19	Johnson & Johnson	214
10.20	KYORIN	215

10.21 M-Biotech 215
10.22 Medtronic 215
10.23 Merck & Co. 217
10.24 Merck KGaA 218
10.25 Microslet 218
10.26 Mitsubishi Tanabe Pharma Corporation 219
10.27 Nipro Diabetes Systems 219
10.28 Novartis 219
10.29 Novo Nordisk 220
10.30 Novocell 221
10.31 ONO Pharmaceutical 221
10.32 Orexigen Therapeutics 222
10.33 Pfizer 223
10.34 ReNeuron 223
10.35 Roche Diagnostics 224
10.36 Sanofi-Aventis 225
10.37 Sensors for Medicine and Science 226
10.38 Siemens 227
10.39 Smiths Medical 227
10.40 Servier 228
10.41 SOOIL Development 228
10.42 Takeda 228
10.43 TheraFuse 229
10.44 Teco Diagnostics 229
10.45 Transition Therapeutics 229
10.46 U.S. Diagnostics 229
10.47 VeraLight 230
10.48 Vivus 230
10.49 Ypsomed Holding 231

Appendix 1: Contact Information for Companies Profiled 232
Appendix 2: Prescribing Patterns for Anti-Hyperglycemic Drugs 238
Appendix 3: Detailed List of Insulins Available 239
Appendix 4: The History of Insulin 240
Appendix 5: Diabetes and Obesity Drugs in Development 245
Appendix 6: Pharmaceutical Sampling Practices 253

INDEX OF FIGURES

Figure 2.1: Worldwide Rates of Diabetes Cases, 2000-2025 17
Figure 2.2: Prevalence of Diabetes by Age in the U.S., 2007 18
Figure 2.3: New Adult Cases of Diabetes Diagnosed in the U.S., 2007 19
Figure 2.4: Distribution of Duration of Diabetes among Adults Aged 18 to 79 Years in the U.S., 2005 20
Figure 2.5: Number of Persons with Diagnosed Diabetes in the U.S., 1980-2007 20
Figure 2.6: Treatment with Insulin or Oral Medication among Adults Diagnosed with Diabetes, 2007 21
Figure 2.7: Rate of New Diabetes Cases among Children in the U.S., 2007 22
Figure 2.8: Expenditure Associated with Diabetes Complications in the U.S., 2007 25
Figure 2.9: Diabetes Death Rate by Race and Sex in the U.S., 1979-2006 27
Figure 3.1: Prevalence of Complications in Diabetics vs. People with Normal Blood Sugar Levels, 2007 34
Figure 3.2: Per Capita Costs for Diabetes-related Complications per Year, 2007 35
Figure 3.3: Total Spending on Healthcare in the U.S., 1960-2008 36
Figure 3.4: Percentage Breakdown of U.S. Healthcare Spending, 2008 36
Figure 3.5: Percentage of U.S. Population that Smokes, 1965-2005 42
Figure 3.6: Heart Disease Death Rate by Race and Sex in the U.S., 1979-2006 42
Figure 3.7: Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007 43
Figure 3.8: Annual Death Rate of U.S. Population from Strokes, 1950-2008 43
Figure 3.9: U.S. Male and Female Population Death Rates from Strokes, 2008 45
Figure 3.10: Annual Death Rate of U.S. Population from Heart Disease, 1950-2008 48
Figure 3.11: Percentage of U.S. Population that is Overweight, 1976-2004 50
Figure 4.1: Medical Research in the U.S. Outpaces the Rest of the World 52
Figure 4.2: Cost of Diabetes in the U.S., 2007 62
Figure 4.3: Top Therapeutic Classes Contributing to Drug Trend, 2007 65
Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2006 65
Figure 5.1: Comparison of the Effects of the Pioglitazone and Rosiglitazone on Lipids 76
Figure 5.2: U.S. Non-Insulin Anti-Diabetes Sales, 2006 83
Figure 5.3: Sales Forecast for the Global Diabetes Market, 1992-2012 84
Figure 6.1: Insulin Pump Market Share, 2007 123
Figure 6.2: Relative Risk of Diabetes Complications by Mean HbA1c 123
Figure 9.1: Relationship between Diabetes Therapy and the Proposed Timeline 195
Figure A3.1: Novo Nordisk's Rising Market Share in the U.S. Insulin Market, 1982-2008 244

INDEX OF TABLES

Table 1.1: Criteria for the Diagnosis of Diabetes 11
Table 2.1: Top Ten Countries in Number of Diabetics (20 to 79 Age Group) in the World, 2007 and 2025 17

Table 2.2: Annual Estimated Cost of Diabetes Care in the U.S., 2007	23
Table 2.3: Impact of Diabetes on Americans	24
Table 2.4: How Diabetes Dollars are Spent in the U.S., 2007	24
Table 3.1: Percentage of GDP Healthcare Spending by Country, 2008	37
Table 3.2: Life Expectancy Rate by Country, 2008	37
Table 3.3: Normal Glucose Values—Fasting State	39
Table 3.4: Percentage of Adults Smokers by Country, 2008	44
Table 3.5: Worldwide Market for Cardiac Care Therapeutics, 2003-2010	45
Table 3.6: Death Rate from Cardiovascular Diseases by Country, 2008	49
Table 4.1: Leading Therapy Classes for R&D, 2008	51
Table 4.2: Pharmaceutical R&D Expenditures by World Region, 1990-2007	52
Table 4.3: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2007	53
Table 4.4: Global Pharmaceutical Sales, 2007	53
Table 4.5: World Pharmaceutical Sales Share by Region, 2007	54
Table 4.6: The World's Top-Selling Drugs (Audited Market), 2007	55
Table 4.7: Pharmaceutical Product Sales by Country Market, 2007	55
Table 4.8: Top Ten Global Pharmaceutical Companies by Global Sales, 2007	56
Table 4.9: Leading Therapy Classes by Global Pharmaceutical Sales (Audited Market), 2007	56
Table 4.10: Leading Ten Therapeutic Classes by U.S. Sales, 2003-2007	56
Table 4.11: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006 and 2007	57
Table 4.12: Top Ten Brand Drugs by U.S. Retail, 2007	57
Table 4.13: Worldwide Anti-Diabetes Drug Market, 2006-2012	58
Table 4.14: Oral Anti-Diabetic Therapy Major World Markets, 2006	59
Table 4.15: The Leading Ten Anti-Diabetics by Sales, 2007	61
Table 4.16: Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes, 2008	61
Table 4.17: Summary of Glucose-Lowering Interventions as Monotherapy	67
Table 5.1: Classes of Non-Insulin Hypoglycemic Agents	70
Table 5.2: Average Dose and Cost Comparison of Hypoglycemic Agents	71
Table 5.3: Relative Efficacy of Diabetes Drugs	72
Table 5.4: Thiazolidinediones Available for Type 2 Diabetes Mellitus	75
Table 5.5: Fixed Drug Combinations	81
Table 5.6: GLP-1 Pipeline: Selected Drugs in Development that Target GLP-1	88
Table 5.7: DPP-IV Inhibitor Pipeline	89
Table 6.1: Available Therapeutic Insulin Alternatives	92
Table 6.2: Worldwide Insulin Sales, 2005-2012	93
Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2007	93
Table 6.4: Worldwide Insulin Sales and Market Share by Company, 2007	94
Table 6.5: U.S. Insulin Sales and Market Share by Company, 2007	94
Table 6.6: U.S. Retail Insulin Sales, 2006-2009	95
Table 6.7: Comparison of Rapid-Acting Insulins	96
Table 6.8: Comparison of Long-Acting Insulins	98
Table 6.9: Pharmacokinetics of Available Insulins	98
Table 6.10: Status of Inhaled Insulin Products, 2009	103
Table 6.11: Key Drivers of the Type 2 Diabetes Insulin Market, 2012	109
Table 6.12: A Comparison of Existing Insulin Delivery Devices	110
Table 6.13: Lancet Characteristics	112
Table 6.14: Lancing Device Characteristics	113
Table 6.15: Insulin Pens	114
Table 6.16: Worldwide Demand for Insulin Injector Pens by Volume, 2006-2010	115
Table 6.17: Injection Aids	118
Table 6.18: Jet Injectors	118
Table 6.19: Leading Insulin Pump Manufacturers	119
Table 6.20: External Insulin Pumps	120
Table 6.21: Comparison of Current Insulin Pumps on the Market	120
Table 6.22: Control Averages by Treatment	122
Table 6.23: Reduced Risk for Various Diseases When Blood Glucose is Near Normal	122
Table 6.24: Worldwide Diabetes Market, 2008	124
Table 6.25: Types of Insulin Pumps on the Market	124
Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies	134
Table 7.2: Cells of the Pancreas	140
Table 7.3: Lipoprotein Risk Levels and Treatment Goals in Adult Patients with Diabetes	142
Table 7.4: Agents for Lowering Lipid Levels in Patients with Dyslipidemia	143
Table 7.5: Suggested Pharmacological Treatment Agents for Hypertension in Patients with Diabetes	144
Table 7.6: Selected Mid-2008 Press Releases on Emerging Anti-Diabetes Agents	146
Table 7.7: Diabetes Agents in the Pipeline	147
Table 7.8: Future Anti-Diabetic Drugs in Late-Stage Development	151
Table 8.1: Laboratory Assessment of Diabetic Vascular Disease	158
Table 8.2: Worldwide Market for Diabetes Self-Testing (Meters, Strips and Lancets), 2004-2012	158
Table 8.3: Market for Glucose Self-Testing in the U.S., 2004-2012	159
Table 8.4: U.S. Sales for OTC Blood Glucose Meters and Strips, 2007	160
Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2008	188
Table 9.2: Selected Licensing Deals in the Diabetes Arena, 2003-2008	190
Table 9.3: Top Therapeutic Categories in U.S. Development, 2008	194
Table 9.4: Pharmaceutical Companies by Number of Products in R&D Pipeline, 2007	194
Table 9.5: Pharmaceutical Companies by Number of Diabetes Products in Development	195
Table 9.6: Selected New Diabetes Drugs in Pipeline, 2007	196
Table 9.7: Comparison of New Molecular Entity Outcomes for FDA and EMEA (Jan 2006 to October 2008)	197

Table 9.8: Upcoming Milestones for Selected Diabetes Drugs 200
Table 9.9: Overview of Blockbuster Drugs Coming Off-Patent, 2008 to 2012 201
Table A1.1: Company Headquarters Contact Information 232
Table A3.1: Current Insulins 239
Table A4.1: Select Archived Press Release Excerpts 243
Table A5.1: The Diabetes/Obesity Pipeline by Developmental Stage, 2009 245

Ordering

Order Online - <http://www.bioseeker.com/market-research-report/diabetes-metabolic-syndrome-and-cardiovascular-disease.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioSeeker Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.bioseeker.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Diabetes, Metabolic Syndrome and Cardiovascular Disease**

Web Address: <http://www.bioseeker.com/market-research-report/diabetes-metabolic-syndrome-and-cardiovascular-disease.html>

Format: PDF

Price: 2890 EUR (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 EUR.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number: _____

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by credit card:

American Express

Master Card

Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

Pay by check:

Please post the check, accompanied by this form, to:

BioMarket Group

Björnnäsvägen 21

11419 STOCKHOLM

SWEDEN

Pay by wire transfer: Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioSeeker Group you are agreeing to our Terms and Conditions at

<http://www.bioseeker.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191